Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The market cap is so tiny on AMBS. That's all that matters and it is worth repeating. People will sell for a variety of reasons...most likely because they either had a great entry point or a much higher entry point and just want to get out. Most investors are impatient. I would drop any conspiracy theories.
Whomever is debating buying this company please don't listen to the negative posts without understand they're most likely hoping it will drop so they can get more. They have their own agendas.
I would pay just a little more attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $12 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
The market cap is so tiny on AMBS. That's all that matters and it is worth repeating. People will sell for a variety of reasons...most likely because they either had a great entry point or a much higher entry point and just want to get out. Most investors are impatient. I would drop any conspiracy theories.
Whomever is debating buying this company please don't listen to the negative posts without understand they're most likely hoping it will drop so they can get more. They have their own agendas.
I would pay just a little more attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $11 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
According to Henri at Hermo Pharma the delivery method has been vastly improved since the GDNF trials. That is why Gill University picked up GDNF again and is in phase II trials. This was the major impediment for GDNF. The beauty is AMBS owns MANF patents and MANF has been shown to be much better at this stage of testing than GDNF was.
I'm still shocked to see a $12 Million market cap given how valuable GDNF was / is and how MANF is showing much better results and AMBS has patent protection. I wouldn't be surprised to see a $100 Million market cap relatively soon.
It's all about the MANF patents. These proteins can be modified to treat the diseases they are trying to treat (like Parkinsons, Myocardial Infarction, Alzheimers, TBI, etc) better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents. Ask yourself why Hermo Pharma felt compelled to challenge their MANF patents. If you don't believe me then read this interview with the partner of Hermo Pharma, who is a VC backed biotech startup and received $700k in funding from the Michael J. Fox Foundation on why they challenged the patents:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
These are his own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein -- variation in 18 amino acid residues allowed, 20 options for each position -- you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Right now MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
AMBS is only worth $12 Million right now.
Versus $250 Million.
Do the math.
And listen to people that know the science like Dr. Rubinfeld who said "I believe that MANF could be one of the biggest successes that I have ever seen". This isn't just some schlub. It's the co-founder of Amgen.
It's all about the MANF patents. These proteins can be modified to treat the diseases they are trying to treat (like Parkinsons, Myocardial Infarction, Alzheimers, TBI, etc) better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents. Ask yourself why Hermo Pharma felt compelled to challenge their MANF patents. If you don't believe me then read this interview with the partner of Hermo Pharma, who is a VC backed biotech startup and received $700k in funding from the Michael J. Fox Foundation on why they challenged the patents:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
These are his own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Right now MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
AMBS is only worth $9 Million right now.
Versus $250 Million.
Do the math.
And listen to people that know the science like Dr. Rubinfeld who said "I believe that MANF could be one of the biggest successes that I have ever seen". This isn't just some schlub. It's the co-founder of Amgen.
It's all about the MANF patents. These proteins can be modified to treat the diseases they are trying to treat (like Parkinsons, Myocardial Infarction, Alzheimers, TBI, etc) better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents. Ask yourself why Hermo Pharma felt compelled to challenge their MANF patents. If you don't believe me then read this interview with the partner of Hermo Pharma, who is a VC backed biotech startup and received $700k in funding from the Michael J. Fox Foundation on why they challenged the patents:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
These are his own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Right now MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
AMBS is only worth $9 Million right now.
Versus $250 Million.
Do the math.
And listen to people that know the science like Dr. Rubinfeld who said "I believe that MANF could be one of the biggest successes that I have ever seen". This isn't just some schlub. It's the co-founder of Amgen.
Again, I didn't expect a big breakout last week because there are a lot of people that bought at the $0.02 level that would be taking profits as well as a lot of people that bought in the $0.06 to $0.08 range that were just looking to bail as soon as a rally came along. Those are the weak hands that lost sight of the big picture. We should rally next week and beyond. I believe it will get to a $75 Million market cap before a partnership is announced. With 225 million shs that equates to a $0.33 per share stock.
It's all about the MANF patents. Whomever is debating buying this company please don't listen to the negative posts without understand they're most likely hoping it will drop so they can get more. They have their own agendas.
I would pay just a little more attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $9 Million right now.
Versus $250 Million.
Do the math.
Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years and put out publications on this wonder protein (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases they are trying to treat (like Parkinsons, Myocardial Infarction, Alzheimers, TBI, etc) better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
Again, I said we would close moderately higher yesterday and today and we did. I didn't expect a breakout only because there were a lot of people that bought at the $0.02 level that would be taking profits as well as a lot of people that bought in the $0.06 to $0.08 range that were just looking to bail as soon as a rally came along. Those are the weak hands that lost sight of the big picture. We rally next week and beyond.
"I love this article. I don't think people realize how important this is...you have words directly from the partner of Hermo Pharma, another biotech firm with funding from the Michael J. Fox Foundation, basically admit that when they challenged AMBS's patent they did it because they thought the patent coverage AMBS has on MANF is too broad. That is, they think that it covers too many potential variations of MANF. The challenge was denied and the judge upheld the patents. That means that anyone working on MANF or anything that has 90% homology (i.e., similarity) to MANF will be forced to deal with AMBS. This is for a protein that has shown significantly better results at the current stage of testing it is in than another drug that was purchased for $250 Million. Do you understand how huge this is? AMBS has a market cap of $9 Million. "
Just saw this above on Yahoo...good post. Here is the article:
http://www.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
The market cap is so tiny on AMBS. That's all that matters and it is worth repeating. People will sell for a variety of reasons...most likely because they either had a great entry point or a much higher entry point and just want to get out. Most investors are impatient. I would drop any conspiracy theories.
Whomever is debating buying this company please don't listen to the negative posts without understand they're most likely hoping it will drop so they can get more. They have their own agendas.
I would pay just a little more attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $8 to $9 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
Again, I think we will close at $0.042 today as the last of the weak hands bail. We rally next week and beyond.
Doesn't matter. The market cap is so tiny on AMBS. That's all that matters. People will sell for a variety of reasons...most likely because they either had a great entry point and or a much higher entry point and just want to get out. Most investors are impatient. I would just drop the conspiracy theories.
Whomever is debating buying this company please don't listen to the negative posts - understand they're most likely hoping it will drop so they can get more. They have their own agendas.
I would pay just a little more attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo PHarma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $8 to $9 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
Again, I think we will close at $0.042 today as the last of the weak hands bail. We rally next week and beyond.
"MANF has the commercial potential to become a blockbuster drug."
There's a reason the co-founder of Amgen says "MANF could be one of the biggest successes that I have ever seen". Patent protection, orphan drug potential, much better results than a $250 Million drug at the same stage of testing...all for $8-9 Million. The market will wake up to this very soon and price it appropriately.
Read the interview with the partner from Hermo Pharma, who recently challenged the MANF patents and lost in court and ask yourself why they would challenge the patents:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
As I mentioned yesterday (http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82451264), I'm today to be another day of churning...I think we close at $0.042 just above resistance as the final weak hands bail. There were a lot of people that bought higher and got spooked out by the pullback and they're just happy to get out. It's keeping a lid on things but that lid is about to lift off.
"MANF has the commercial potential to become a blockbuster drug."
There's a reason the co-founder of Amgen says "MANF could be one of the biggest successes that I have ever seen". Patent protection, orphan drug potential, much better results than a $250 Million drug at the same stage of testing...all for $8 Million. The market will wake up to this very soon and price it appropriately.
Read the interview with the partner from Hermo Pharma, who recently challenged the MANF patents and lost in court and ask yourself why they would challenge the patents:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
Again, I'm expecting one more day of churning...I think we close at $0.042 tomorrow just above resistance as the final weak hands bail. There were a lot of people that bought higher and got spooked out by the pullback.
AMBS's patents on MANF are the reason this is going much, much higher.
Seeking Alpha Interview with Hermo Pharma Partner:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
I'm not really looking for a potential buyout; however I think it's hard to ignore the relative valuation as well as test results when compared to GDNF. I'm just looking at relatively valuations and patent protection. They have a patent on MANF, which was upheld in court against a competitor of theirs, Hermo Pharma. There was a very interesting interview posted on Seeking Alpha (see above) with the partner at Hermo Pharma (again, the company that challenged their patents) that I think sheds a lot of light on this company's patents and how undervalued it is.
MANF has been shown to be significantly better in test results than GDNF was at this stage of testing. GDNF was developed by a company that was purchased by Amgen for over $250 Million while GDNF was in pre clinical trial stage (just like where AMBS is at). GDNF was halted later on during trials because it couldn't be delivered to the brain effectively, yet it was recently picked up by Gill University and is in phase II trials. According to the guy from Hermo Pharma, Gill Univ has been able to deliver it to the brain much more effectively both directly and via intra nasal delivery. As he said "Yes, there is interest in the big pharma. The field is burdened by the stigma caused by GDNF failures. Over the past 3-4 years, we have discussed with a large number of companies, small-mid-big pharma, and it has become very clear that if one of the small biotechs can provide proof of efficacy in human PD patients, this will bring the big players back in the game."
The moment they show actual studies on the delivery improvements or if AMBS can show it from their testing then MANF immediately goes to the head of the list because it has been shown to be far more effective. And guess who has patents on MANF?
I'm willing to discount this significantly when comparing it to GDNF just to be ultra conservative and say it's only worth $75 Million. Still that makes this a 9 bagger from here. I don't think the market fully grasps the importance of that interview posted on Seeking Alpha. There is a reason why Hermo Pharma challenged their patents and a reason why the co-Founder of Amgen stated that MANF could be a blockbuster and "potentially one of the biggest successes I have ever seen".
In the next few days I expect people with big gains from the $0.02 area and with big losses from up above to continue to sell. Those are what I would refer to as weaker hands. People like Rainmaker or Crowbar or whomever will say its dilution. That's nonsense and they know it. I think the stock will churn a bit but it is hard to ignore the undervaluation here. Don't listen to people bashing the stock because they want in as well. It will be much higher soon.
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus." said Henri Huttunen, Ph.D., CSO and Partner from Hermo Pharma Oy Ltd., a privately owned, venture capital backed company based in Finland working on therapeutic approaches for currently untreatable medical needs, particularly Parkinson's disease.
"As Henri mentioned, they challenged the patents because they believed that they covered too many possible variants of the protein and it therefore "causes "an undue burden" to anyone who would like to test these variants for activity". The only way I can interpret this is that anyone looking to test different variants of MANF will be forced to go through AMBS as it has patents "that cover all sequences with 90% homology to MANF"."
Just curious what your take is on this.
I like how you're trying spread fear so you can buy lower. Good luck with that.
AMBS's MANF patents are the reason this is going much higher.
Seeking Alpha Interview with Hermo Pharma Partner:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
I'm not really looking for a potential buyout; however I think it's hard to ignore the relative valuation as well as test results when compared to GDNF. I'm just looking at relatively valuations and patent protection. They have a patent on MANF, which was upheld in court against a competitor of theirs, Hermo Pharma. There was a very interesting interview posted on Seeking Alpha (see above) with the partner at Hermo Pharma (again, the company that challenged their patents) that I think sheds a lot of light on this company's patents and how undervalued it is.
MANF has been shown to be significantly better in test results than GDNF was at this stage of testing. GDNF was developed by a company that was purchased by Amgen for over $250 Million while GDNF was in pre clinical trial stage (just like where AMBS is at). GDNF was halted later on during trials because it couldn't be delivered to the brain effectively, yet it was recently picked up by Gill University and is in phase II trials. According to the guy from Hermo Pharma, Gill Univ has been able to deliver it to the brain much more effectively both directly and via intra nasal delivery. As he said "Yes, there is interest in the big pharma. The field is burdened by the stigma caused by GDNF failures. Over the past 3-4 years, we have discussed with a large number of companies, small-mid-big pharma, and it has become very clear that if one of the small biotechs can provide proof of efficacy in human PD patients, this will bring the big players back in the game."
The moment they show actual studies on the delivery improvements or if AMBS can show it from their testing then MANF immediately goes to the head of the list because it has been shown to be far more effective. And guess who has patents on MANF?
I'm willing to discount this significantly when comparing it to GDNF just to be ultra conservative and say it's only worth $75 Million. Still that makes this a 9 bagger from here. I don't think the market fully grasps the importance of that interview posted on Seeking Alpha. There is a reason why Hermo Pharma challenged their patents and a reason why the co-Founder of Amgen stated that MANF could be a blockbuster and "potentially one of the biggest successes I have ever seen".
In the next few days I expect people with big gains from the $0.02 area and with big losses from up above to continue to sell. People like Rainmaker will say its dilution. That's nonsense and he knows it. Those are what I would refer to as weaker hands. I think the stock will churn a bit but it is hard to ignore the undervaluation here. Don't listen to people bashing the stock because they want in as well.
I still think we have a day or two more of weak hands selling. Remember what some people have been through: some bought at $0.04 after the first drop, watched it go to $0.07 then fall to $0.018. Those people are just happy to get out at breakeven. Then you have others that bought at the $0.018-0.02 lows and they're taking profits. I think we get a breakout next week. Just be patient.
Remember AMBS owns rights to the MANF patents and anything that has a 90% homology (i.e., similarity) to the MANF protein. Anyone that wants to work on the MANF protein is forced to go through AMBS via a license deal. MANF has had significantly better test results than GDNF at this stage of testing, which is the stage at which GDNF was bought out for $250 Million.
There is a reason Hermo Pharma challenged those patents and there's a reason why the co-founder of Amgen has called MANF potentially "the biggest success I have ever seen" and it could be a "blockbuster drug"
Seeking Alpha Interview with Hermo Pharma Partner:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
I've been in this stock for about 6 weeks now...I bailed but then got in around $0.03 and bought more at $0.02. Haven't posted here because I was banned for whatever reason. Anyway, I'm not really looking for a potential buyout. I'm just looking at relatively valuations and patent protection. They have a patent on MANF, which was upheld in court against a competitor of theirs, Hermo Pharma. There was a very interesting interview posted on Seeking Alpha (see above) with the partner at Hermo Pharma (again, the company that challenged their patents) that I think sheds a lot of light on this company's patents and how undervalued it is.
MANF has been shown to be significantly better in test results than GDNF was at this stage of testing. GDNF was developed by a company that was purchased by Amgen for over $250 Million while GDNF was in pre clinical trial stage (just like where AMBS is at). GDNF was halted later on during trials because it couldn't be delivered to the brain effectively, yet it was recently picked up by Gill University and is in phase II trials. According to the guy from Hermo Pharma, Gill Univ has been able to deliver it to the brain much more effectively both directly and via intra nasal delivery. As he said "Yes, there is interest in the big pharma. The field is burdened by the stigma caused by GDNF failures. Over the past 3-4 years, we have discussed with a large number of companies, small-mid-big pharma, and it has become very clear that if one of the small biotechs can provide proof of efficacy in human PD patients, this will bring the big players back in the game."
The moment they show actual studies on the delivery improvements or if AMBS can show it from their testing then MANF immediately goes to the head of the list because it has been shown to be far more effective. And guess who has patents on MANF?
I'm willing to discount this significantly when comparing it to GDNF just to be ultra conservative and say it's only worth $75 Million. Still that makes this a 9 bagger from here. I don't think the market fully grasps the importance of that interview posted on Seeking Alpha. There is a reason why Hermo Pharma challenged their patents and a reason why the co-Founder of Amgen stated that MANF could be a blockbuster and "potentially one of the biggest successes I have ever seen".
In the next few days I expect people with big gains from the $0.02 area and with big losses from up above to continue to sell. Those are what I would refer to as weaker hands. I think the stock will churn a bit but it is hard to ignore the undervaluation here.
You forget that GDNF and plenty of others have been bought out or signed partnership deals while in pre human clinical trials. If it is a partnership deal the partner pays development costs and retains X% of royalties. GDNF was purchased for $250 Million during the animal testing stage and MANF has been shown in a variety of publications to be a significantly better solution than GDNF. AMBS owns patents on MANF and any variety of protein that has 90% homology to MANF. That means anyone that wants to work on it or any similar variation of it will have to go through AMBS. I'd suggest reading the interview with the Hermo Pharma partner posted a few days ago:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
Seeking Alpha Interview with Hermo Pharma Partner:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
I've been in this stock for about 6 weeks now...I bailed but then got in around $0.03 and bought more at $0.02. Haven't posted here because I was banned for whatever reason. Anyway, I'm not really looking for a potential buyout. I'm just looking at relatively valuations and patent protection. They have a patent on MANF, which was upheld in court against a competitor of theirs, Hermo Pharma. There was a very interesting interview posted on Seeking Alpha (see above) with the partner at Hermo Pharma (again, the company that challenged their patents) that I think sheds a lot of light on this company's patents and how undervalued it is.
MANF has been shown to be significantly better in test results than GDNF was at this stage of testing. GDNF was developed by a company that was purchased by Amgen for over $250 Million while GDNF was in pre clinical trial stage (just like where AMBS is at). GDNF was halted later on during trials because it couldn't be delivered to the brain effectively, yet it was recently picked up by Gill University and is in phase II trials. According to the guy from Hermo Pharma, Gill Univ has been able to deliver it to the brain much more effectively both directly and via intra nasal delivery. As he said "Yes, there is interest in the big pharma. The field is burdened by the stigma caused by GDNF failures. Over the past 3-4 years, we have discussed with a large number of companies, small-mid-big pharma, and it has become very clear that if one of the small biotechs can provide proof of efficacy in human PD patients, this will bring the big players back in the game."
The moment they show actual studies on the delivery improvements or if AMBS can show it from their testing then MANF immediately goes to the head of the list because it has been shown to be far more effective. And guess who has patents on MANF?
I'm willing to discount this significantly when comparing it to GDNF just to be ultra conservative and say it's only worth $75 Million. Still that makes this a 9 bagger from here. I don't think the market fully grasps the importance of that interview posted on Seeking Alpha. There is a reason why Hermo Pharma challenged their patents and a reason why the co-Founder of Amgen stated that MANF could be a blockbuster and "potentially one of the biggest successes I have ever seen".
In the next few days I expect people with big gains from the $0.02 area and with big losses from up above to continue to sell. Those are what I would refer to as weaker hands. I think the stock will churn a bit but it is hard to ignore the undervaluation here.
Yahoo data is notoriously unreliable. Typically on big spikes you will see a majority of the float traded in one day. ambs was only doing about 50 mill on those big days a month ago. The float is a max of 140 based on number of shared held by insiders and an estimate of shares held by people on this board.
Either way it doesn't matter. This should be valued at least at 75 mill based on patent value on MANF relative to GDNF buyout price.
There's no way the float is that high. Insiders I believe own roughly 50 million shares and I know of about 30 million held by people on this board. That means float is 140 million at most.
Seeking Alpha Interview with Hermo Pharma Partner:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
I've been in this stock for about 6 weeks now...I bailed but then got in around $0.03 and bought more at $0.02. Haven't posted here because I was banned for whatever reason. Anyway, I'm not really looking for a potential buyout. I'm just looking at relatively valuations and patent protection. They have a patent on MANF, which was upheld in court against a competitor of theirs, Hermo Pharma. There was a very interesting interview posted on Seeking Alpha (see above) with the partner at Hermo Pharma (again, the company that challenged their patents) that I think sheds a lot of light on this company's patents and how undervalued it is.
MANF has been shown to be significantly better in test results than GDNF was at this stage of testing. GDNF was developed by a company that was purchased by Amgen for over $250 Million while GDNF was in pre clinical trial stage (just like where AMBS is at). GDNF was halted later on during trials because it couldn't be delivered to the brain effectively, yet it was recently picked up by Gill University and is in phase II trials. According to the guy from Hermo Pharma, Gill Univ has been able to deliver it to the brain much more effectively both directly and via intra nasal delivery. As he said "Yes, there is interest in the big pharma. The field is burdened by the stigma caused by GDNF failures. Over the past 3-4 years, we have discussed with a large number of companies, small-mid-big pharma, and it has become very clear that if one of the small biotechs can provide proof of efficacy in human PD patients, this will bring the big players back in the game."
The moment they show actual studies on the delivery improvements or if AMBS can show it from their testing then MANF immediately goes to the head of the list because it has been shown to be far more effective. And guess who has patents on MANF?
I'm willing to discount this significantly when comparing it to GDNF just to be ultra conservative and say it's only worth $75 Million. Still that makes this a 9 bagger from here. I don't think the market fully grasps the importance of that interview posted on Seeking Alpha. There is a reason why Hermo Pharma challenged their patents and a reason why the co-Founder of Amgen stated that MANF could be a blockbuster and "potentially one of the biggest successes I have ever seen".
In the next few days I expect people with big gains from the $0.02 area and with big losses from up above to continue to sell. Those are what I would refer to as weaker hands. I think the stock will churn a bit but it is hard to ignore the undervaluation here.
Alright I bailed. Sold over the past 20 minutes. Sick of watching this crap. It's not looking good. Maybe I can get back in around $0.03 or so. Good luck but I'm out.
Not looking so hot. Who here is bailing? Looks like people are losing confidence.
Email from CEO about financing:
Saw this on Yahoo:
"Hello **********,
I understand your concern. However, we do not feel it is appropriate to look at it this way. We have not actually diluted the shareholders. We have issued very minimal stock with this financing. If you look at the terms of the transaction, shares are to be issued at $0.10 on the convertible note and we have the ability to repay the note if we raise capital on better terms in the future.
I hope you can understand that not every decision is an easy one. The reality is that we weighed this decision very heavily and came up with the number in a very sobering manner so as to look at worse-case scenarios. Funding a multi-billion dollar potential drug candidate will likely take dilutive financings, and we are working to ensure that we raise the necessary funding on the best terms possible so as to ensure limited dilution. We are hopeful the market will respond positively to future developments and that we will be able to fund product development and ongoing operations on the best terms possible so as to minimize dilution. We planned for the worse, but certainly are working to make sure the best possible outcome is achieved for our shareholders.
Best Regards,
Gerald"
Are longs getting nervous?
What's everyone's price target?
Again, its all about market caps with penny stocks. Conservatively: Mkt Cap of AMBS = $10 Million
*Assuming 250 million shares outstanding which is probably too high.
Compare this to some other penny stocks with far less potential:
TAGG - Current market cap of $24 Million; peak was over $100 Million
MJNA - Current market cap of $71 Million; peak was $95 Million
CBIS - Current market cap of $61 Milion; peak was almost $70 Million
When you take into account what Dr. Joseph Rubinfeld, co-founder of Amgen said ("I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug.") on November 6th, do you really think that the market cap should only be $10 Million? We have plenty of other companies pre trial or offering crap to customers like the penny stocks above that are trading at upwards of $100 Million or more.
It's all about Market Cap. Conservatively: Mkt Cap of AMBS = $10 Million
*Assuming 250 million shares outstanding which is probably too high.
Compare this to some other penny stocks with far less potential:
TAGG - Current market cap of $24 Million; peak was over $100 Million
MJNA - Current market cap of $71 Million; peak was $95 Million
CBIS - Current market cap of $61 Milion; peak was almost $70 Million
When you take into account what Dr. Joseph Rubinfeld, co-founder of Amgen said ("I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug.") on November 6th, do you really think that the market cap should only be $10 Million? We have plenty of other companies pre trial or offering crap to customers like the penny stocks above that are trading at upwards of $100 Million or more.
Ask yourself if a company with a product described by the co-founder of AMGN as what "could be one of the biggest successes that I have ever seen" should be worth 1/10th of each of those companies above.
Come on people lets think for a second here.
Conservatively: Mkt Cap of AMBS = $10 Million
*Assuming 250 million shares outstanding which is probably too high.
Compare this to some other penny stocks with far less potential:
TAGG - Current market cap of $24 Million; peak was over $100 Million
MJNA - Current market cap of $71 Million; peak was $95 Million
CBIS - Current market cap of $61 Milion; peak was almost $70 Million
When you take into account what Dr. Joseph Rubinfeld, co-founder of Amgen said ("I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug.") on November 6th, do you really think that the market cap should only be $10 Million? We have plenty of other companies pre trial or offering crap to customers like the penny stocks above that are trading at upwards of $100 Million or more.
Ask yourself if a company with a product described by the co-founder of AMGN as what "could be one of the biggest successes that I have ever seen" should be worth 1/10th of each of those companies above.
Come on people lets think for a second here.
i've been having issues with my computer all morning. this stupid monitor i got a few months back is connecting to the mac fine but when i close the mac to view stuff on the monitor it keeps saying "no signal" and i have tried rebooting several times. pain in the a$$
weird my post got cut off...i asked "is anyone throwing in the towel?"
Throwing in the towel.
Conservatively the market cap on Ambs is roughly $10 Million (assuming 250 million shares outstanding which is probably too high). Compare this to some other penny stocks with far less potential:
TAGG - Current market cap of $24 Million; peak was over $100 Million
MJNA - Current market cap of $71 Million; peak was $95 Million
CBIS - Current market cap of $61 Milion; peak was almost $70 Million
When you take into account what Dr. Joseph Rubinfeld, co-founder of Amgen said ("I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug.") on November 6th, do you really think that the market cap should only be $10 Million? We have plenty of other companies pre trial or offering crap to customers like the penny stocks above that are trading at upwards of $100 Million or more.
Ask yourself if a company with a product described by the co-founder of AMGN as what "could be one of the biggest successes that I have ever seen" should be worth 1/10th of each of those companies above.
Come on people lets think for a second here.
Good news this week: Coverage in Seeking Alpha, exposure at the CNS Summit, Corporate Update including:
*Potential partnerships with big pharma
*Orphan drug status potential
*Potential new grants
*Positive data coming out in December
Looks like acorisk and the shorts are trying their best to bash before going long. Acorisk claims that the stock has already rallied from 0.001 to 0.08 which is an 80 fold claim; however, he fails to look at a chart. Lets go to Stockcharts.com shall we:
http://stockcharts.com/h-sc/ui?s=AMBS&p=D&b=5&g=0&id=p36622096623
The chart works in increments of 0.005 down at the bottom of it. Clearly it looks like the bottom was 0.005. The current price is 0.041. 8 fold higher. While that is a nice run, we're looking at a market cap of about $10 Million, assuming 250 Million shares outstanding, which by the way is conservative. I know, I know, but they have 1 Billion authorized right? We're really not that stupid to just assume that because they have 200 million shares but 1 Billion authorized that outstanding should equal authorized are we? Seriously? Especially when they JUST RAISED CAPITAL?
When you take into account what Dr. Joseph Rubinfeld, co-founder of Amgen said ("I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug.") on November 6th, do you really think that the market cap should only be $10 Million? We have plenty of other companies pre trial that are trading at upwards of $100 Million.
Now lets compare to some other penny stock with far less potential:
TAGG - Current market cap of $24 Million; peak was over $100 Million
MJNA - Current market cap of $71 Million; peak was $95 Million
CBIS - Current market cap of $61 Milion; peak was almost $70 Million
Ask yourself if a company with a product described by the co-founder of AMGN as what "could be one of the biggest successes that I have ever seen" should be worth 1/10th of each of those companies above.
Come on people lets think for a second here.
Whoa we have some press coverage!!!
http://m.seekingalpha.com/article/1016221-finding-a-cure-for-parkinson-s
I just got word that John will be presenting at 12 noon tomorrow. Anyone able to attend?
I confirmed that John is speaking on Sunday...see email below:
"As of yesterday, I was due to present at 11:30 am, Sunday, November 18. However, this may change. There are last minute changes being made in the roster of speakers for this oral Pharma/Biotech session, I will ping you as soon as I know the exact time.
John Commissiong
--
John W. Commissiong, PhD
CSO
Amarantus Therapeutics Inc
C/O Mol Med Res Inst
552 Del Rey Avenue
Sunnyvale
CA 94085"
Anyone else see a bullish pennant formation?
Per Gerald they will be hiring someone dedicated to shareholder issues so he can focus on partnerships / fund raising. I believe this is going to be laid out to shareholders in their update next week. Should be quite a bit of information on the company next week. Looking forward to it.
Care to wager?